RCP
TOVX icon

Rothschild Capital Partners’s Theriva Biologics TOVX Stock Holding History

Rothschild Capital Partners’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3
Closed -$52K – 73
2016
Q3 		$52K Buy
+3
New +$44.9K 0.02% 76

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Rothschild Capital Partners's TOVX Position: Q4 2016 in Review

Rothschild Capital Partners sold out of Theriva Biologics (TOVX) in Q4 2016, closing a stake of 3 shares — an estimated $52K sold.

Rothschild Capital Partners first reported a position in TOVX in Q3 2016 and held it in 1 quarter. The position peaked at $52K in Q3 2016. 70 funds tracked by Wall St. Rank hold TOVX as of Q4 2016.

  • Rothschild Capital Partners reported no remaining Theriva Biologics position as of Q4 2016 after selling out during the quarter.
  • Rothschild Capital Partners sold 3 Theriva Biologics shares in Q4 2016, an estimated $52K.
  • Rothschild Capital Partners first reported a position in Theriva Biologics in Q3 2016 and held it in 1 quarter.
  • Rothschild Capital Partners's Theriva Biologics position peaked at $52K in Q3 2016.
  • 70 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2016.

Based on Rothschild Capital Partners's 13F filing for Q4 2016, filed 30 Jan 2017.